Ipamorelin Raised a Hormone but Showed No Clear Gain

The only fair human trial missed its main goal

Drug researchers made Ipamorelin from a group of five amino acids, the small pieces your body also uses to make proteins, because they wanted a narrower hormone effect. In pigs, it didn't raise cortisol, the body's stress hormone, prolactin, which helps make breast milk, or one other hormone, even above 200 times the amount needed for the main effect ^[6]. Older test peptides called GHRP-6 and GHRP-2 had wider effects; GHRP means growth-hormone-releasing peptide.

The human record is thin. Ipamorelin has never been approved to treat people. Its only published Phase 2 trial—an early check for benefit and short-term harm—had 114 adults after bowel surgery. The drug missed the trial's main goal ^[14]. Another small study put it into a vein and watched how fast it left ^[15]. Most other work used animals or cells kept in a dish.

WADA, the world sport drug-testing body, bans Ipamorelin under its growth-hormone rule called Section S2. This page gives you findings, not a dose or advice for your care.

Five amino acids make up Ipamorelin

Five amino acids make up Ipamorelin. Your body uses the same small pieces to build proteins. The paper marks the pieces at spots 1, 3, and 4 as harder for blood to cut apart. The numbers 1, 3, and 4 are positions in the drug, not amounts. They don't tell you whether it helps you.

The makers began with an older peptide and removed two pieces from its middle. Ipamorelin copies part of ghrelin, the hormone that helps bring on hunger. Growth-gland cells, some nerves, and pancreas cells can read that message. CJC-1295 is built differently and copies the brain's growth-hormone message. Remembering that split helped me make sense of claims that could affect your choice.

Ipamorelin starts a short growth-hormone burst

Ipamorelin copies part of ghrelin, the hunger hormone. Growth-gland cells read that message and release growth hormone. CJC-1295 copies a different message. Using both kinds brought a larger burst than either alone in early work ^[5][7].

The first test used sleeping rats and awake pigs. Ipamorelin matched an older growth-hormone peptide called GHRP-6. GHRP means growth-hormone-releasing peptide. Yet Ipamorelin didn't raise cortisol, the stress hormone, or one other hormone, even above 200 times the amount needed for its main effect ^[6]. GHRP-6 and GHRP-2 raised those hormones at high amounts.

Gut nerves and pancreas cells can also read the ghrelin message. In cells taken from the body, Ipamorelin made pancreas cells release more insulin. In mice, it helped form fat even without growth hormone ^[2]. Animal and cell results can't tell you what will happen in your body.

One small study put Ipamorelin into a vein in healthy men. Half left the blood in about 2 hours. Growth hormone was highest near 40 minutes ^[15]. Those blood readings alone don't show a health benefit.

Animal findings didn't become a clear human benefit

The first work used rats and pigs. Even above 200 times the amount needed for its main effect, Ipamorelin didn't raise the stress hormone or one other hormone. It still released about as much growth hormone as the older peptide called GHRP-6 ^[6].

The early human blood study was tiny. Only 8 healthy men received each amount through a vein. Half the drug left in about 2 hours, and the hormone burst was highest near 40 minutes ^[15]. The test didn't ask whether anyone felt better.

The bone study used rats. Adult female rats got 18, 90, or 450 micrograms per day, split three times daily for 15 days. Their bones grew lengthwise at 42, 44, 50, and 52 micrometers per day as the amount rose. IGF-1 didn't change. Blood signs that can show bone being built or worn down didn't change either ^[16]. You can't assume an older man's bones would respond the same way.

The only Phase 2 human trial failed its main test. Phase 2 means an early trial looking for benefit while watching short-term harm. The test had 114 adults after open or keyhole bowel surgery. They got 0.03 milligrams for each kilogram of body weight through a vein, twice daily for up to 7 days. People given Ipamorelin ate sooner on average, but chance could explain the gap. New health problems were common in both groups. A placebo looks like treatment but contains no active drug. No harm stood out as caused by Ipamorelin, but the main test failed ^[14].

The newest study used ferrets. In 2024, they got 1 to 3 milligrams for each kilogram of body weight in the belly. Ipamorelin cut drug-linked weight loss by about 24% on the last test day, after the weight loss had begun. It didn't stop vomiting ^[12].

The heart warning came from another drug. A 28-day rat test found more heart-muscle harm as the amount rose. That drug worked through the same kind of cell message, but it wasn't Ipamorelin ^[13]. The result warns about the wider group. It doesn't prove your heart would be harmed by Ipamorelin.

User stories leave the long-term risks unanswered

People using Ipamorelin for research made these reports. No fair trial has checked them. Some mention deeper sleep, vivid dreams, less soreness, faster rest after exercise, or a leaner build. Others describe a red face, head rush, tingling, swelling, hunger, tiredness, foggy thinking, skin soreness near the shot, or less effect after months. Their amounts and sources aren't known. You can't rely on these as trial results.

Published work leaves these risks open. Here is what may matter to you.

• Cancer. Ipamorelin releases growth hormone ^[6]. That tells the liver to make IGF-1, a protein that helps cells grow. The concern centers on IGF-1 because the rise might help a hidden tumor grow. No Ipamorelin study has shown that event.
• Diabetes. Growth hormone can make insulin work less well. In cells taken from the body, Ipamorelin also made pancreas cells release insulin without growth hormone ^[2]. We don't know the overall effect when someone's blood sugar is already hard to control.
• Heart illness or failure. A 28-day study found heart-muscle harm in rats given a related drug ^[13]. The drug wasn't Ipamorelin. No long Ipamorelin study has cleared that worry.
• Hunger and fat. Ghrelin helps govern hunger. In mice, Ipamorelin also helped make fat without growth hormone ^[2]. More hunger or fat could matter if either already harms your health.
• Long use. The only fair human trial was a 7-day study with 114 patients ^[14]. The early blood study had 8 people at each amount ^[15]. No Phase 3 trial—a large late test used to confirm benefit and harm before approval—exists. There is no human blood study of shots under the skin. A research supply may not meet medicine-making rules.
• Cortisol stayed low. Cortisol is a hormone that helps your body answer stress. Unlike GHRP-6 and GHRP-2, two older growth-hormone peptides, Ipamorelin didn't raise it much or lift one other hormone at very high amounts ^[6]. That avoids one old worry. It doesn't clear the rest.

Animal work outweighs the human proof

Ipamorelin provides the short burst in the CJC-1295 and Ipamorelin pair. Animal work showed growth hormone rising while some other hormones stayed low ^[6]. One small human study watched the drug in blood ^[15]. Its Phase 2 trial—an early human test—missed the main goal ^[14].

Claims about sleep, repair, or a leaner body go beyond that proof. Read CJC-1295 for the longer-lasting half. The comparison page shows which findings came from people, animals, or cells and what that means for you.